Growth & profitability
- Revenue has grown 41.0% per year over the past 5 years.
- Operating margin has expanded, at 9.9% in the latest year.
GYRE Financials GYRE THERAPEUTICS, INC.
15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $117M | $10M | 95.4% | 9.9% | -$180000 | — | $37M |
| 2024 | $106M | $18M | 96.3% | 15.3% | -$6M | — | $12M |
| 2023 | $113M | -$85M | 95.9% | -59.3% | $17M | — | $34M |
| 2022 | $102M | $4M | 95.3% | 9.0% | $6M | — | $25M |
| 2021 | $7M | -$88M | 0.0% | -1197.8% | -$85M | — | $44M |
| 2020 | $21M | -$56M | 0.0% | -273.9% | — | — | $30M |
| 2019 | — | -$55M | — | — | -$44M | — | $15M |
| 2018 | $6000 | -$30M | 0.0% | -563700.0% | -$29M | — | $31M |
| 2017 | $1M | -$22M | 0.0% | -2143.6% | -$20M | — | $14M |
| 2016 | — | -$17M | — | — | — | — | $10M |
| 2015 | — | -$15M | — | — | — | — | $29M |
| 2014 | — | -$7M | — | — | — | $0 | $2M |
| 2013 | — | -$10M | — | — | -$41M | $1M | $3M |
| 2012 | — | -$7M | — | — | -$65M | $2M | $3M |
| 2011 | — | -$9M | — | — | -$85M | $3M | $107M |
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $23M | -$10M | 94.6% | -41.5% | $3M | — | $38M |
| Dec '25 | $37M | -$1M | 95.3% | 0.3% | -$6M | — | $37M |
| Sep '25 | $31M | $6M | 94.7% | 22.7% | $4M | — | $40M |
| Jun '25 | $27M | $2M | 95.7% | 8.1% | $2M | — | $36M |
| Mar '25 | $22M | $4M | 95.9% | 10.3% | -$251000 | — | $15M |
| Dec '24 | $28M | $598000 | 95.8% | 2.4% | -$3M | — | $12M |
| Sep '24 | $25M | $3M | 96.2% | 16.6% | $1M | — | $16M |
| Jun '24 | $25M | $5M | 96.9% | 12.7% | -$7M | — | $16M |
| Mar '24 | $27M | $10M | 96.4% | 29.7% | $3M | — | $30M |
| Dec '23 | $27M | -$82M | 95.4% | -337.5% | $1M | — | $34M |
| Sep '23 | $32M | $8M | 96.3% | 39.8% | $6M | — | $2M |
| Jun '23 | $29M | $4M | 96.3% | 17.0% | $2M | — | $7M |
| Mar '23 | $25M | $4M | 95.5% | 26.7% | $9M | — | $8M |
| Dec '22 | — | -$28M | — | — | — | — | $25M |
| Sep '22 | — | -$5M | — | — | — | — | $23M |
| Jun '22 | — | $52M | — | — | — | — | $75M |
| Mar '22 | $794000 | -$15M | 0.0% | -1851.5% | — | — | $35M |
| Dec '21 | $2M | -$20M | 0.0% | -832.5% | -$18M | — | $44M |
| Sep '21 | $2M | -$25M | 0.0% | -1097.4% | -$22M | — | $59M |
| Jun '21 | $1M | -$20M | 0.0% | -1759.2% | — | — | $74M |
Valuation over time
How the market has priced GYRE against its own fundamentals since 2023-10 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-earnings ratio has fallen from 156.1× (Oct '23) to 61.0× (Jun '26).
- The price-to-sales ratio has fallen from 6.6× (Oct '23) to 5.2× (Jun '26).
- The dividend yield has fallen from 6.7% (Oct '23) to 1.8% (Dec '23).
P/E
P/S
Dividend yield %
Frequently asked questions
Is GYRE growing its revenue and profit?
Over the past 5 years, GYRE THERAPEUTICS, INC.'s revenue has grown 41.0% per year. These are computed facts, not advice.
How much debt does GYRE have?
As of FY2025, GYRE THERAPEUTICS, INC. reported — of total debt against $37M of cash.
What is GYRE's profit margin?
In FY2025, gross margin was 95.4%, operating margin 9.9%, and net margin 8.5%.
What is GYRE's P/E ratio?
As of Jun '26, GYRE THERAPEUTICS, INC. traded at a price-to-earnings ratio of about 61.0× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S and dividend yield have moved with the share price. These are computed facts, not advice.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.